|
1
|
Mombelli S, Kwiatkowski F, Abrial C,
Wang-Lopez Q, de Boissieu P, Garbar C, Bensussan A and Curé H:
Prognostic factors in operable breast cancer treated with
neoadjuvant chemotherapy: Towards a quantification of residual
disease. Oncology. 88:261–272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kwee RM and Kwee TC: Role of imaging in
predicting response to neoadjuvant chemotherapy in gastric cancer.
World J Gastroenterol. 20:1650–1656. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosenblatt R, Sherif A, Rintala E,
Wahlqvist R, Ullén A, Nilsson S and Malmström PU: Nordic Urothelial
Cancer Group: Pathologic downstaging is a surrogate marker for
efficacy and increased survival following neoadjuvant chemotherapy
and radical cystectomy for muscle-invasive urothelial bladder
cancer. Eur Urol. 61:1229–1238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tanaka K, Miyata H, Yamasaki M, Sugimura
K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M and
Doki Y: Circulating miR-200c levels significantly predict response
to chemotherapy and prognosis of patients undergoing neoadjuvant
chemotherapy for esophageal cancer. Ann Surg Oncol. 20:(Suppl 3).
S607–S615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sardi JE, Boixadera MA and Sardi JJ:
Neoadjuvant chemotherapy in cervical cancer: A new trend. Curr Opin
Obstet Gynecol. 17:43–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Panici P Benedetti, Bellati F, Pastore M,
Manci N, Musella A, Pauselli S, Angelucci M, Muzii L and Angioli R:
An update in neoadjuvant chemotherapy in cervical cancer. Gynecol
Oncol. 107:(Suppl 1). S20–S22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shen SN, Wang LF, Jia YF, Hao YQ, Zhang L
and Wang H: Upregulation of microRNA-224 is associated with
aggressive progression and poor prognosis in human cervical cancer.
Diagn Pathol. 8:692013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Punt S, Fleuren GJ, Kritikou E, Lubberts
E, Trimbos JB, Jordanova ES and Gorter A: Angels and demons: Th17
cells represent a beneficial response, while neutrophil IL-17 is
associated with poor prognosis in squamous cervical cancer.
Oncoimmunology. 4:e9845392015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen YJ, Shen MR, Chen YJ, Maa MC and Leu
TH: Eps8 decreases chemosensitivity and affects survival of
cervical cancer patients. Mol Cancer Ther. 7:1376–1385. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watari H, Kanuma T, Ohta Y, Hassan MK,
Mitamura T, Hosaka M, Minegishi T and Sakuragi N: Clusterin
expression inversely correlates with chemosensitivity and predicts
poor survival in patients with locally advanced cervical cancer
treated with cisplatin-based neoadjuvant chemotherapy and radical
hysterectomy. Pathol Oncol Res. 16:345–352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Benedetti-Panici P, Greggi S, Colombo A,
Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F,
Zola P, Mangioni C and Landoni F: Neoadjuvant chemotherapy and
radical surgery versus exclusive radiotherapy in locally advanced
squamous cell cervical cancer: Results from the Italian multicenter
randomized study. J Clin Oncol. 20:179–188. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuo DY, Blank SV, Christos PJ, Kim M,
Caputo TA, Pothuri B, Hershman D, Goldman N, Ivy PS, Runowicz CD,
et al: Paclitaxel plus oxaliplatin for recurrent or metastatic
cervical cancer: A New York Cancer Consortium Study. Gynecol Oncol.
116:442–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Köhler C, Oppelt P, Favero G, Morgenstern
B, Runnebaum I, Tsunoda A, Schmittel A, Schneider A, Mueller M and
Marnitz S: How much platinum passes the placental barrier? analysis
of platinum applications in 21 patients with cervical cancer during
pregnancy. Am J Obstet Gynecol. 213:206.e1-5. 2015. View Article : Google Scholar
|
|
15
|
Lorusso D, Petrelli F, Coinu A,
Raspagliesi F and Barni S: A systematic review comparing cisplatin
and carboplatin plus paclitaxel-based chemotherapy for recurrent or
metastatic cervical cancer. Gynecol Oncol. 133:117–123. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vacca A, Ribatti D, Iurlaro M, Merchionne
F, Nico B, Ria R and Dammacco F: Docetaxel versus paclitaxel for
antiangiogenesis. J Hematother Stem Cell Res. 11:103–118. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rose PG, Blessing JA, Ball HG, Hoffman J,
Warshal D, DeGeest K and Moore DH: A phase II study of docetaxel in
paclitaxel-resistant ovarian and peritoneal carcinoma: A
gynecologic oncology group study. Gynecol Oncol. 88:130–135. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Verschraegen CF, Sittisomwong T, Kudelka
AP, Guedes ED, Steger M, Nelson-Taylor T, Vincent M, Rogers R,
Atkinson EN and Kavanagh JJ: Docetaxel for patients with
paclitaxel-resistant Müllerian carcinoma. J Clin Oncol.
18:2733–2739. 2000.PubMed/NCBI
|
|
19
|
Takekida S, Fujiwara K, Nagao S, Yamaguchi
S, Yoshida N, Kitada F, Kigawa J, Terakawa N and Nishimura R: Phase
II study of combination chemotherapy with docetaxel and carboplatin
for locally advanced or recurrent cervical cancer. Int J Gynecol
Cancer. 20:1563–1568. 2010.PubMed/NCBI
|
|
20
|
Wei H, Wang N, Zhang Y, Wang S, Pang X,
Zhang J, Luo Q, Su Y and Zhang S: Clinical significance of Wnt-11
and squamous cell carcinoma antigen expression in cervical cancer.
Med Oncol. 31:9332014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jeong BK, Huh SJ, Choi DH, Park W, Bae DS
and Kim BG: Prognostic value of different patterns of squamous cell
carcinoma antigen level for the recurrent cervical cancer. Cancer
Res Treat. 45:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Zhou J, Huang K, Tang F, Zhou H,
Wang S, Jia Y, Sun H, Ma D and Li S: The predictive value of serum
squamous cell carcinoma antigen in patients with cervical cancer
who receive neoadjuvant chemotherapy followed by radical surgery: A
single-institute study. PLoS One. 10:e01223612015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin M, Hou Y, Zhang T, Cui C, Zhou X, Sun
F, Li H, Li X, Zheng J, Chen X, et al: Evaluation of chemotherapy
response with serum squamous cell carcinoma antigen level in
cervical cancer patients: A prospective cohort study. PLoS One.
8:e549692013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gómez R, Ossa CA, Montoya ME, Echeverri C,
Ángel G, Ascuntar J, Borrero M, Gil M, Herrera S, Gutiérrez E, et
al: Impact of immunohistochemistry-based molecular subtype on
chemosensitivity and survival in Hispanic breast cancer patients
following neoadjuvant chemotherapy. Ecancermedicalscience.
9:5622015.PubMed/NCBI
|
|
25
|
Kim HS and Song YS: International
federation of gynecology and obstetrics (FIGO) staging system
revised: What should be considered critically for gynecologic
cancer? J Gynecol Oncol. 20:135–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Persijn van Meerten EL, Gelderblom H
and Bloem JL: RECIST revised: Implications for the radiologist. A
review article on the modified RECIST guideline. Eur Radiol.
20:1456–1467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Suminami Y, Kishi F, Sekiguchi K and Kato
H: Squamous cell carcinoma antigen is a new member of the serine
protease inhibitors. Biochem Biophys Res Commun. 181:51–58. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chien J, Aletti G, Baldi A, Catalano V,
Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, et
al: Serine protease HtrA1 modulates chemotherapy-induced
cytotoxicity. J Clin Invest. 116:1994–2004. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thompson D, Chien J, Staub J, Molina J and
Shridhar V: Loss of HtrA3, a serine protease involved in
smoking-related lung cancer: Implications for chemoresistance. Clin
Cancer Res. 12:B702006.
|
|
30
|
Clausen T, Southan C and Ehrmann M: The
HtrA family of proteases: Implications for protein composition and
cell fate. Mol Cell. 10:443–455. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeda A, Yamamoto T, Nakamura Y,
Takahashi T and Hibino T: Squamous cell carcinoma antigen is a
potent inhibitor of cysteine proteinase cathepsin L. FEBS Lett.
359:78–80. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bell-McGuinn KM, Garfall AL, Bogyo M,
Hanahan D and Joyce JA: Inhibition of cysteine cathepsin protease
activity enhances chemotherapy regimens by decreasing tumor growth
and invasiveness in a mouse model of multistage cancer. Cancer Res.
67:7378–7385. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moore KN, Herzog TJ, Lewin S, Giuntoli RL,
Armstrong DK, Rocconi RP, Spannuth WA and Gold MA: A comparison of
cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB,
recurrent or persistent cervical cancer. Gynecol Oncol.
105:299–303. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stewart DJ: Mechanisms of resistance to
cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hong JH, Tsai CS, Chang JT, Wang CC, Lai
CH, Lee SP, Tseng CJ, Chang TC and Tang SG: The prognostic
significance of pre- and posttreatment SCC levels in patients with
squamous cell carcinoma of the cervix treated by radiotherapy. Int
J Radiat Oncol Biol Phys. 41:823–830. 1998. View Article : Google Scholar : PubMed/NCBI
|
